|Featured Video : Colorado State University (CSU) receives record $42.5M gift from John and Leslie Malone to propel regenerative medicine |
Philanthropists and equestrians, John and Leslie Malone, have a stable of world-class dressage horses. Some of their championship steeds have received stem cell treatments to repair stressed and injured joints, thereby inspiring the Malone’s to make this “historic” donation to CSU. The featured video depicts the Malone’s vision to utilize stem cells in animal studies to benefit animals and humanity. This an unusual gift and food for thought for institutional development officers. CSU will become a leader in translational medicine. Read article here.
|TIME: Most cancer is beyond your control, breakthrough study finds. Insights into cancer stem cells |
This research received huge attention in global media. Johns Hopkins researchers Christian Tomasetti and Bert Vogelstein published an article in Science that Time Journalist Alice Park described as “likely to turn our understanding of cancer- and how it should be treated- on its head.” Here is an excerpt from the TIME article:
Indeed, when they charted out the stem cell data for 31 types of tissues, they found a dramatic connection between the two — the more stem cells the tissue had, the higher its incidence of cancer over a person’s life time on average. “Think of cancer as the risk of having an accident if you are driving a car,’ says Tomasetti, a biostatistician who holds positions in the department of oncology at Johns Hopkins Kimmel Cancer Center and the Johns Hopkins Bloomberg School of Public Health. “If you drive the car on a cross country trip, your risk of an accident is much higher than if you take a local trip to the grocery store. The risk correlates to the length of the trip. The trip to the grocery store might be thought of as bone cancer, which has few stem cell divisions. While the cross country trip might be more like colon cancer, which has many more cell divisions.”
|Reuters: Israel's BrainStorm says stem cell drug benefits most patients in ALS trial |
“Israel's BrainStorm Cell Therapeutics said final results from a clinical trial of its adult stem cell treatment in amyotrophic lateral sclerosis (ALS) were positive, with most patients showing a slowing in the disease's progression.”
|Nikkei Asian Review: Biotech flocking to Japan to sell regenerative medicine |
This short article describes how RegMed companies such as ReNeuron, Pluristem and Medipost are setting up trials in Japan to take advantage of the liberal regulatory regime. Here is an eye-opening excerpt:
The Japanese market for regenerative medicine, which stood at 9 billion yen ($74.1 million) in 2012, is projected to expand to 95 billion yen in 2020 and 1 trillion yen in 2030, according to the industry ministry. The government of Prime Minister Shinzo Abe has positioned regenerative medicine as a pillar of its growth strategy. By attracting foreign companies with high-level skills, Japanese industry could get a technological boost, too.
|Speed matters: California’s stem cell agency officially launches CIRM 2.0 |
CIRM is making some big changes in the way it does business.Here are the highlights, as reported by the Agency:
Speed: In addition in to reducing the time to funding to 120 days, new clinical stage projects may be submitted to CIRM year round instead of only once or twice a year as in the past. Applications simply have to be filed by 5pm PT on the last business day of the month to be eligible for consideration in that round of review. If you miss the deadline one month, you only have to wait 30 days for the next one.
Partnerships: Under CIRM 2.0, the Agency will not act as a passive funding source, but instead will be an active investor, devoting significant internal resources and leveraging its vast external team of world-class subject matter experts to advance the projects it selects. This will result in a true partnership that both accelerates programs and gives them the greatest opportunity for success.
Patients: Each project will be partnered with a project-specific Clinical Advisory Panel (CAP) to help advise and guide it forward. Importantly, every panel will include at least one patient advisor with first-hand experience of the specific condition, who will provide input, recommendations and the appropriate sense of urgency that can only come from the unique perspective of someone living with the disease.
|UKNow: University of Kentucky study disputes previous theories on loss of muscle stem cells and aging |
In research published in Nature Medicine, Kentucky researchers studied Sarcopenia, an affliction involving age-related loss of muscle mass impacting elderly people, and came up with surprising results. Is it now time to augment macrophages in muscle training?
|UC San Diego Health System: Fat isn’t all bad: skin adipocytes help protect against infections |
Did you know that fat cells under our skin might protect us from bacteria? That was a finding of UC San Diego researchers in a study published in Science. According to professor Richard Gallo “The key is that we now know this part of the immune response puzzle. It opens fantastic new options for study. For example, current drugs designed for use in diabetics might be beneficial to other people who need to boost this aspect of immunity. Conversely, these findings may help researchers understand disease associations with obesity and develop new strategies to optimize care.”